Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08ECW
|
|||
| Former ID |
DIB016348
|
|||
| Drug Name |
Racotumomab
|
|||
| Synonyms |
P3 MAb, CIM; 1E10 anti-idiotypic MAb, Center of Molecular Immunology
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1], [2] | |
| Company |
The Center of Molecular Immunology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tumor antigen NGcGM3 (NGcGM3) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7995). | |||
| REF 2 | Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012; 2: 150. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.